Pig Islet Cells Show Promise in Early Safety Trial for Type 1 Diabetes

A new clinical trial tested whether insulin-producing cells from specially bred pigs could be safely transplanted into people with Type 1 diabetes. Early results suggest the approach may be viable, though more research is needed.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsimmunotherapyadvancements

Key takeaways

Ten people received transplants of insulin-producing islet cells from pigs in a safety study, with some followed for over 10 years.
No transmission of pig viruses or transplant-related infections occurred in any recipient or their family members during long-term monitoring.
The procedure was well-tolerated with only temporary changes in liver function and mild side effects—no serious adverse events were reported.
The pigs came from a specially bred, disease-screened colony to minimize infection risk, addressing a major historical concern with pig-to-human transplants.
This work is still in early stages; it evaluated safety rather than whether the transplanted cells successfully controlled blood sugar.

Why Pig Cells Matter for Diabetes

Type 1 diabetes develops when the immune system destroys the beta cells in the pancreas that produce insulin. One potential solution is transplanting insulin-producing islet cells from a donor—but human donor organs are scarce. Pig islets have long interested researchers because pigs are similar to humans in size and physiology, and pigs can be bred in controlled conditions.

However, pig-to-human transplants (called xenotransplantation) have faced serious hurdles: the risk that pig viruses could jump to humans, severe inflammatory reactions in the body, and the need for strong long-term immune suppression. This new trial focused on whether these challenges could be overcome.

How the Trial Worked

Ten people with Type 1 diabetes received transplants of neonatal (newborn) pig islet cells. The cells were injected through a catheter into the liver, where they could potentially take hold and produce insulin. Participants were divided into two groups receiving different cell doses.

The pigs came from a specially bred colony that was negative for PERV (porcine endogenous retrovirus), a virus of long-standing concern in xenotransplantation research. The pigs were raised in pathogen-free conditions and screened extensively before their cells were used. Recipients took a combination of immune-suppressing medications and also received the participants' own immune cells (regulatory T cells) to help tolerance.

The study team monitored recipients and their spouses for over 5 years, with 7 participants tracked for more than 10 years.

Key Safety Findings

No PERV transmission occurred in any recipient or their family members during the entire follow-up period. No transplant-related infections were detected either. This addresses one of the historic concerns about pig cell transplants—the theoretical risk that pig viruses could enter human circulation and spread.

The procedure itself was well-tolerated. While some recipients experienced temporary changes in liver function and blood clotting markers (expected given the transplant location and anticoagulation therapy), these were mild and transient. No serious adverse events were reported.

What This Means—and What Remains Unknown

This trial demonstrates that pig islet transplantation can be performed safely in humans, at least in the short to medium term. The combination of a carefully screened pig source, rigorous donor screening, and immune-management strategies appears to have contained the biological risks that have historically limited xenotransplantation.

However, this trial was designed to assess safety, not whether the transplanted cells successfully controlled blood sugar or reduced the need for insulin. Those questions—central to whether this becomes a viable treatment—remain to be answered in future studies. As with any emerging transplant strategy, long-term outcomes and the durability of the transplants over decades of a patient's life are still being evaluated.

Evidence label

Source: Xenotransplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.